Showing results (11-20 of 28) with videos related to
Sort By:
Pageof 3
Thrombosis Research|May 5, 2007
Comparison of two immunochemical assays for measuring thrombin-activatable fibrinolysis inhibitor concentration with a functional assay in patients with acute coronary syndromeMika Skeppholm, N Håkan Wallén, Karin Malmqvist, et al.Journal of Hypertension|September 1, 2007
Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA)Richard Müller-Brunotte, Thomas Kahan, Begoña López, et al.Journal of Hypertension|December 23, 2004
Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatmentUlrika Liljedahl, Thomas Kahan, Karin Malmqvist, et al.American Journal of Hypertension|January 1, 2004
Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trialLisa Kurland, Ulrika Liljedahl, Julia Karlsson, et al.Journal of Hypertension|March 23, 2002
Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trialLisa Kurland, Håkan Melhus, Julia Karlsson, et al.American Journal of Hypertension|May 23, 2002
Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trialLisa Kurland, Håkan Melhus, Julia Karlsson, et al.Journal of Hypertension|October 3, 2002
The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trialPär Hallberg, Julia Karlsson, Lisa Kurland, et al.Clinical Physiology and Functional Imaging|February 8, 2017
Plasma biomarker levels and non-obstructive coronary artery disease determined by coronary computed tomography angiographyElin B Brolin, Stefan Agewall, Kerstin Cederlund, et al.The British Journal of Clinical Psychology|April 16, 2022
Initial evaluation of a therapist-supported online cognitive therapy self-help for patients with taboo obsessionsKlara Olofsdotter Lauri, Kristina Aspvall, Ingvill Bagøien Hustad, et al.Journal of Hypertension|March 18, 2003
B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trialPär Hallberg, Lars Lind, Karl Michaëlsson, et al.Pageof 3